Details of the Drug

General Information of Drug (ID: DMMZXIW)

Drug Name

Rabeprazole

Synonyms

Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]
Gastrinoma	2C10.1	Approved	[2]
Peptic ulcer	DA61	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antiulcer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

359.4

Logarithm of the Partition Coefficient (xlogp)

1.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 52% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 4 mL/min/kg [4]
Elimination: 0% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 - 2 hours (in plasma) [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.5 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.037% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.22 L/kg [4]

Chemical Identifiers

Formula: C18H21N3O3S
IUPAC Name: 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
Canonical SMILES: CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
InChI: InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
InChIKey: YREYEVIYCVEVJK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5029
ChEBI ID: CHEBI:8768
CAS Number: 117976-89-3
DrugBank ID: DB01129
TTD ID: D0KL4J
VARIDT ID: DR01195
INTEDE ID: DR1387
ACDINA ID: D00578

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric H(+)/K(+) ATPase alpha (ATP4A)	TTF1QVM	ATP4A_HUMAN	Inhibitor	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Bacterial infection

ICD Disease Classification

1A00-1C4Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Gastric H(+)/K(+) ATPase alpha (ATP4A)	DTT	ATP4A	1.42E-02	-0.15	-1.5
Breast cancer resistance protein (ABCG2)	DTP	BCRP	3.39E-04	-4.15E+00	-3.65E+00
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	5.51E-02	1.95E-01	1.20E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.90E-02	-3.45E-01	-1.49E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rabeprazole

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Kanamycin	DM2DMPO	Moderate	Increased risk of hypomagnesemia by the combination of Rabeprazole and Kanamycin.	Bacterial infection [1A00-1C4Z]	[9]
Cefpodoxime	DMJUNY5	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[10]
Bacampicillin	DMP54C7	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Bacampicillin.	Bacterial infection [1A00-1C4Z]	[10]
-----------

Coadministration of a Drug Treating the Disease Different from Rabeprazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Rabeprazole due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[11]
Paromomycin	DM1AGXN	Moderate	Increased risk of hypomagnesemia by the combination of Rabeprazole and Paromomycin.	Amoebiasis [1A36]	[9]
Posaconazole	DMUL5EW	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Posaconazole.	Aspergillosis [1F20]	[12]
Vismodegib	DM5IXKQ	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Vismodegib.	Basal cell carcinoma [2C32]	[13]
Pexidartinib	DMS2J0Z	Major	Decreased absorption of Rabeprazole due to altered gastric pH caused by Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[14]
Lapatinib	DM3BH1Y	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Lapatinib.	Breast cancer [2C60-2C6Y]	[11]
HKI-272	DM6QOVN	Major	Decreased absorption of Rabeprazole due to altered gastric pH caused by HKI-272.	Breast cancer [2C60-2C6Y]	[13]
Bosutinib	DMTI8YE	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Bosutinib.	Breast cancer [2C60-2C6Y]	[15]
Panitumumab	DMQPD1F	Moderate	Increased risk of hypomagnesemia by the combination of Rabeprazole and Panitumumab.	Colorectal cancer [2B91]	[9]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Rabeprazole caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[16]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Rabeprazole caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Itraconazole	DMCR1MV	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Itraconazole.	Fungal infection [1F29-1F2F]	[18]
GS-5885	DMSL3DX	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by GS-5885.	Hepatitis virus infection [1E50-1E51]	[13]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Rabeprazole caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[19]
Fosamprenavir	DM4W9B3	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Fosamprenavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Rabeprazole caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Rilpivirine	DMJ0QOW	Major	Decreased absorption of Rabeprazole due to altered gastric pH caused by Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Raltegravir	DMYURI6	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Raltegravir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Iron	DMAP8MV	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Iron.	Iron deficiency anaemia [3A00]	[24]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Rabeprazole caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[25]
Ceritinib	DMB920Z	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Ceritinib.	Lung cancer [2C25]	[26]
Dacomitinib	DMOH8VY	Major	Decreased absorption of Rabeprazole due to altered gastric pH caused by Dacomitinib.	Lung cancer [2C25]	[11]
Selpercatinib	DMZR15V	Major	Decreased absorption of Rabeprazole due to altered gastric pH caused by Selpercatinib.	Lung cancer [2C25]	[11]
Acalabrutinib	DM7GCVW	Major	Decreased absorption of Rabeprazole due to altered gastric pH caused by Acalabrutinib.	Mature B-cell lymphoma [2A85]	[27]
Ponatinib	DMYGJQO	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Ponatinib.	Mature B-cell lymphoma [2A85]	[13]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Rabeprazole caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[28]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Rabeprazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[29]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Rabeprazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[11]
Nilotinib	DM7HXWT	Moderate	Increased risk of hypomagnesemia by the combination of Rabeprazole and Nilotinib.	Myeloproliferative neoplasm [2A20]	[30]
Dasatinib	DMJV2EK	Major	Decreased absorption of Rabeprazole due to altered gastric pH caused by Dasatinib.	Myeloproliferative neoplasm [2A20]	[31]
Prasugrel	DM7MT6E	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[32]
Polythiazide	DMCH80F	Moderate	Increased risk of hypomagnesemia by the combination of Rabeprazole and Polythiazide.	Oedema [MG29]	[9]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Rabeprazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[33]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Rabeprazole caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[34]
Choline salicylate	DM8P137	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Choline salicylate.	Postoperative inflammation [1A00-CA43]	[35]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Rabeprazole caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[36]
Riociguat	DMXBLMP	Moderate	Decreased absorption of Rabeprazole due to altered gastric pH caused by Riociguat.	Pulmonary hypertension [BB01]	[37]
Axitinib	DMGVH6N	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Axitinib.	Renal cell carcinoma [2C90]	[38]
Salsalate	DM13P4C	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Salsalate.	Rheumatoid arthritis [FA20]	[35]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Rabeprazole caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Vandetanib	DMRICNP	Minor	Decreased absorption of Rabeprazole due to altered gastric pH caused by Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[13]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Rabeprazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[39]
Plazomicin	DMKMBES	Moderate	Increased risk of hypomagnesemia by the combination of Rabeprazole and Plazomicin.	Urinary tract infection [GC08]	[9]
-----------


⏷ Show the Full List of 43 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Potassium chloride	E00074	4873	Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Carbonic acid disodium salt	E00199	10340	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium hydroxide	E00374	73981	Adsorbent; Buffering agent
Magnesium oxide	E00232	14792	Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 34 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Rabeprazole 20 mg tablet	20 mg	Delayed Release Oral Tablet	Oral
Rabeprazole 10 mg granules	10 mg	Oral Granules	Oral
Rabeprazole 5 mg granules	5 mg	Oral Granules	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7290).
2	Rabeprazole FDA Label
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23.
7	Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
8	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
9	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
10	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
13	Cerner Multum, Inc. "Australian Product Information.".
14	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
15	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
16	Cerner Multum, Inc. "Canadian Product Information.".
17	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
18	Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
19	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
20	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
21	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
22	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
23	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
24	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
25	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
26	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
27	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
28	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
29	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
30	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
31	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
32	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
33	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
34	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
35	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
36	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
37	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
38	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.